Identification of Novel Biomarkers and Candidate Drug in Ovarian Cancer

Chia-Jung Li; Li-Te Lin; Pei-Yi Chu; An-Jen Chiang; Hsiao-Wen Tsai; Yi-Han Chiu; Mei-Shu Huang; Zhi-Hong Wen; Kuan-Hao Tsui

doi:10.3390/jpm11040316

Identification of Novel Biomarkers and Candidate Drug in Ovarian Cancer

J Pers Med. 2021 Apr 19;11(4):316. doi: 10.3390/jpm11040316.

Authors

Chia-Jung Li^{1

2}, Li-Te Lin^{1

2

3}, Pei-Yi Chu^{4

5

6

7}, An-Jen Chiang¹, Hsiao-Wen Tsai^{1

2}, Yi-Han Chiu⁸, Mei-Shu Huang¹, Zhi-Hong Wen⁹, Kuan-Hao Tsui^{1

2

3

10

11

12}

Affiliations

¹ Department of Obstetrics and Gynaecology, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan.
² Institute of Biopharmaceutical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan.
³ Department of Obstetrics and Gynaecology, National Yang-Ming University School of Medicine, Taipei 112, Taiwan.
⁴ School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei 242, Taiwan.
⁵ Department of Pathology, Show Chwan Memorial Hospital, Changhua 500, Taiwan.
⁶ Department of Health Food, Chung Chou University of Science and Technology, Changhua 510, Taiwan.
⁷ National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan.
⁸ Department of Microbiology, Soochow University, Taipei 111, Taiwan.
⁹ Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804, Taiwan.
¹⁰ Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan.
¹¹ Department of Pharmacy and Master Program, College of Pharmacy and Health Care, Tajen University, Pingtung County 907, Taiwan.
¹² Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.

Abstract

This paper investigates the expression of the CREB1 gene in ovarian cancer (OV) by deeply excavating the gene information in the multiple databases and the mechanism thereof. In short, we found that the expression of the CREB1 gene in ovarian cancer tissue was significantly higher than that of normal ovarian tissue. Kaplan-Meier survival analysis showed that the overall survival was significantly shorter in patients with high expression of the CREB1 gene than those in patients with low expression of the CREB1 gene, and the prognosis of patients with low expression of the CREB1 gene was better. The CREB1 gene may play a role in the occurrence and development of ovarian cancer by regulating the process of protein. Based on differentially expressed genes, 20 small-molecule drugs that potentially target CREB1 with abnormal expression in OV were obtained from the CMap database. Among these compounds, we found that naloxone has the greatest therapeutic value for OV. The high expression of the CREB1 gene may be an indicator of poor prognosis in ovarian cancer patients. Targeting CREB1 may be a potential tool for the diagnosis and treatment of OV.

Keywords: CREB1; bioinformatics; drug perturbation; ovarian cancer.